Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur Emilie CHOTARD

📍 Rennes (35)HospitalierRPPS 10101199825
📊 Reconnaissance scientifique : 3/100📝 8 articles publiés📚 HAL (7)

✨ Profil synthétique

IA · 30/04/2026

Le Docteur Emilie CHOTARD est une rhumatologue hospitalière à Rennes, avec des recherches axées sur la goutte et l'hyperuricémie. Ses publications sur PubMed incluent des cas cliniques et des séries de cas sur la goutte. Elle a un h-index de 3 sur OpenAlex, basé sur 8 publications.

Expertises présumées

  • Goutte
  • Hyperuricémie
  • Rhumatologie hospitalière
  • Recherche sur l'acide urique
  • Pathologies du métabolisme urique
  • Rhumatoides

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

3

h articles cités ≥ h fois chacun. Un h de 3 = 3 publications avec 3+ citations.

Citations

323

Publications

8

i10-index

2

Thématiques principales

  • Ion Transport and Channel Regulation ×2
  • Gout, Hyperuricemia, Uric Acid ×2
  • Hippo pathway signaling and YAP/TAZ ×2
  • Calpain Protease Function and Regulation ×2
  • Rheumatoid Arthritis Research and Therapies ×1

Affiliations FR : Inserm · Université Paris Cité · Sorbonne Paris Cité

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome

    Rheumatology (Oxford, England) · 2022

    📚 17 citations🎯 RCR 2.05
    Lire l'abstract Crossref ↓

    Abstract Objective Gitelman syndrome (GS) is the most frequent salt-wasting genetic tubulopathy and a source of hypokalaemia and hypomagnesemia. Chondrocalcinosis (CC) is a frequent feature of GS. The aim of our study was to determine the prevalence, distribution patterns, clinical phenotypes and risk factors for CC in GS. Methods This prospective study of a cohort of 57 patients with GS included a systematic screening for CC by peripheral joint radiography, cervical spine CT and joint US. The prevalence of cervical C1–C2 CC by CT was compared between 33 GS patients and sex- and age-matched controls. Clinical and biochemical features were analysed to identify factors associated with CC. Results Mean (s.d.) age of patients was 46.5 (12.4) years, 66.7% were women and 93.0% carried SLC12A3 mutations. Mean serum magnesium level was 0.60 (0.30) mmol/l. CC was observed in 79% of patients, with the highest prevalence at the cervical spine (81.8%) followed by the knee (52.6%), wrist (50.9%), ankle (38.6%), TM joint (36.4%), shoulder (33.3%), hip (22.8%), elbow (14.0%) and sclerochoroid (12.1%). Prevalence of CC at the C1–C2 level was higher in the GS cohort than control group (72.7% vs 9.1%) (adjusted odds ratio 21.0, 95% CI 2.8, 156.1, P = 0.003). Independent factors associated with CC were low serum magnesium level and age. Conclusion GS was associated with widespread CC, favoured by aging and hypomagnesemia. The C1–C2 level was the most affected site. Follow-up of this unique cohort will help understanding the clinical consequences of CC, especially the precise characterization of pyrophosphate arthropathy.

  • 2
    From skin to microscope, case report of a rare manifestation of tophaceous gout: Miliary gout

    International journal of rheumatic diseases · 2024

    📚 4 citations🎯 RCR 1.81🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractJoint symptoms associated with gout, mostly characterized by joint flare‐ups, are well known. Tophi represent the main cutaneous manifestation of gout, most often associated with a chronic and inadequately controlled disease. On rare occasions, atypical skin manifestations may occur. We present the case of a miliary form of gout in a 36‐year‐old man known to have hyperuricemia. Microscopic direct analysis of the skin material revealed the presence of monosodium urate (MSU) crystals. Rash disappeared with corticosteroid therapy in parallel with joint symptoms recovery. Knowledge of this unusual gout‐related skin disease is essential to diagnosing uncommon presentations of gout, which sometimes occur before joint symptoms. This case highlights the importance of sampling any skin lesion suspected of being tophus, for MSU crystal identification, and provides a definitive diagnosis.

  • 3
    A calpain-6/YAP axis in sarcoma stem cells that drives the outgrowth of tumors and metastases

    Cell death & disease · 2022

    📚 2 citations🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractSarcomas include cancer stem cells, but how these cells contribute to local and metastatic relapse is largely unknown. We previously showed the pro-tumor functions of calpain-6 in sarcoma stem cells. Here, we use an osteosarcoma cell model, osteosarcoma tissues and transcriptomic data from human tumors to study gene patterns associated with calpain-6 expression or suppression. Calpain-6 modulates the expression of Hippo pathway genes and stabilizes the hippo effector YAP. It also modulates the vesicular trafficking of β-catenin degradation complexes. Calpain-6 expression is associated with genes of the G2M phase of the cell cycle, supports G2M-related YAP activities and up-regulated genes controlling mitosis in sarcoma stem cells and tissues. In mouse models of bone sarcoma, most tumor cells expressed calpain-6 during the early steps of tumor out-growth. YAP inhibition prevented the neoformation of primary tumors and metastases but had no effect on already developed tumors. It could even accelerate lung metastasis associated with large bone tumors by affecting tumor-associated inflammation in the host tissues. Our results highlight a specific mechanism involving YAP transcriptional activity in cancer stem cells that is crucial during the early steps of tumor and metastasis outgrowth and that could be targeted to prevent sarcoma relapse.

Publications scientifiques (7) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal5

Case report / série1

Goutte1

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.